{
    "relation": [
        [
            "",
            "STARTED",
            "Ongoing",
            "COMPLETED",
            "NOT COMPLETED",
            "Physician Decision",
            "Withdrawal by Subject",
            "Death",
            "Ongoing"
        ],
        [
            "Part A: Dabrafenib 75 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part B: Dabrafenib 75 mg + Trametinib 1 mg",
            "6",
            "2",
            "0",
            "6",
            "1",
            "0",
            "3",
            "2"
        ],
        [
            "Part B: Dabrafenib 150 mg + Trametinib 1 mg",
            "23",
            "10",
            "0",
            "23",
            "3",
            "0",
            "10",
            "10"
        ],
        [
            "Part B: Dabrafenib 150 mg + Trametinib 1.5 mg",
            "27",
            "9",
            "0",
            "27",
            "4",
            "2",
            "12",
            "9"
        ],
        [
            "Part B: Dabrafenib 150 mg + Trametinib 2 mg",
            "79",
            "28",
            "0",
            "79",
            "13",
            "2",
            "36",
            "28"
        ],
        [
            "Part C (Randomized): Dabrafenib 150 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part C (Randomized): Dabrafenib 150 mg + Trametinib 1 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part C (Randomized): Dabrafenib 150 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part D: Dabrafenib 75 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Part D: Dabrafenib 150 mg + Trametinib 2 mg",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ]
    ],
    "pageTitle": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01072175?sect=X015_09&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 5,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981753.21/warc/CC-MAIN-20150728002301-00215-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 848967647,
    "recordOffset": 848945228,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Part A (Drug-Drug Interaction) Participant Flow for 5 periods Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD. Part D: Dabrafenib 150 mg + Trametinib 2 mg Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD. Part D: Dabrafenib 75 mg + Trametinib 2 mg Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29. Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29. Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to",
    "textAfterTable": "\u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 Ongoing \u00a0 \u00a0 0 \u00a0 \u00a0 2 \u00a0 \u00a0 10 \u00a0 \u00a0 9 \u00a0 \u00a0 28 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}